At meeting held on 21 January 2020
The Board of Glenmark Pharmaceuticals at its meeting held on 21 January 2020 has approved the sale of gynaecology business in India and Nepal for a cash consideration of Rs 115 crore to Bangalore based Integrace, the portfolio company of PE firm, Ture North. The transaction is expected close on or before 31 March 2020.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
